Loading clinical trials...
Loading clinical trials...
The Optimal Treatment for Treatment-resistant Schizophrenia
To explore the curative effect and safety of Risperidone，aripiprazole，sodium valproate，modified electroconvulsive therapy(MECT), or Magnetic seizure therapy(MST) with Clozapine in the treatment of treatment-resistant schizophrenia， and to provide the basis for clinical medication.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
DTliu
Shanghai, China
Start Date
November 1, 2016
Primary Completion Date
September 1, 2019
Completion Date
September 1, 2019
Last Updated
March 13, 2019
150
ESTIMATED participants
Risperidone with Clozapine
DRUG
Aripiprazole with Clozapine
DRUG
sodium valproate with Clozapine
DRUG
modified electroconvulsive therapy(MECT) with Clozapine
DEVICE
Magnetic seizure therapy(MST) with Clozapine
DEVICE
clozapine
DEVICE
Lead Sponsor
Shanghai Mental Health Center
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions